HeartFlow’s shares fell 19.1% after earnings, despite raised full-year revenue and gross-margin guidance. The transcript does not identify a specific disappointment; management’s outlook was raised, so the selloff cannot be attributed to a guidance cut or a stated slowdown based on the available information.
HeartFlow’s Q2 revenue growth and product utilization notably exceeded expectations, driving a 41% surge in the stock. Accelerating commercial adoption across both Plaque and FFRCT segments underpinned a meaningful upward revision in full-year guidance.